Clinical Trial Update: A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study [Phase 1]

View source ↗

Summary

Phase 1 pilot dose-escalation trial evaluating a densified combination of docetaxel and epirubicin in metastatic breast cancer (MODEL1), completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED